• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
Citation: FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
shu

Advances in drug delivery systems for the treatment of liver fibrosis

More Information
    Graphical Abstract
    • Abstract
  • Liver fibrosis is a major disease that affects human health. Currently, drugs used for the treatment of hepatic fibrosis have such problems as low drug solubility, lack of liver specificity and possible occurrence of side-effects. In order to improve the anti-fibrosis therapeutic efficacy, various nano-drug delivery systems and targeting strategies are explored in liver fibrosis therapy. This review summarizes the drug delivery systems and targeting strategies that have been applied to liver fibrosis therapy in recent years from the types of carriers and modified ligands, which serve as a basis of designing safe and effective drug delivery systems for liver fibrosis therapy.
    • FullText(HTML)
    • References (57)
  • [1]
    Mokdad AA,Lopez AD,Shahraz S,et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010:a systematic analysis[J].BMC Med,2014,12(1):145.
    [2]
    Hernandez-Gea V,Friedman SL.Pathogenesis of liver fibrosis[J].Annu Rev Pathol,2011,6(1):425-456.
    [3]
    Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
    [4]
    Raghu G,Johnson WC,Lockhart D,et al.Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone:results of a prospective,open-label phase II study[J].Am J Respir Crit Care Med,1999,159(4 Pt 1):1061-1069.
    [5]
    van Dijk F,Olinga P,Poelstra K,et al.Targeted therapies in liver fibrosis:combining the best parts of platelet-derived growth factor BB and interferon gamma[J].Front Med(Lausanne),2015,2:72.
    [6]
    Lin TsT,Gao DY,Liu YC,et al.Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis[J].J Control Release,2016,221:62-70.
    [7]
    Bisht S,Khan MA,Bekhit M,et al.A polymeric nanoparticle formulation of curcumin(NanoCurc)ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation[J].Lab Invest,2011,91(9):1383-1395.
    [8]
    Kumar V,Mondal G,Dutta R,et al.Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis[J].Biomaterials,2016,76:144-156.
    [9]
    Kumar V,Mundra V,Mahato R I.Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.[J].Pharm Res,2014,31(5):1158-1169.
    [10]
    Kong WH,Park K,Lee MY,et al.Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis[J].Biomaterials,2013,34(2):542-551.
    [11]
    Jiménez Calvente C,Sehgal A,Popov Y,et al.Specific hepatic delivery of procollagen 1(I)small interfering RNA in lipid-like nanoparticles resolves liver fibrosis[J].Hepatology,2015,62(4):1285-1297.
    [12]
    Li FQ,Su H,Wang J,et al.Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting[J].Int J Pharm,2008,349(1/2):274-82.
    [13]
    Lam PL,Kok SHL,Gambari R,et al.Evaluation of berberine/bovine serum albumin nanoparticles for liver fibrosis therapy[J].Green Chem,2015,17:1640-1646.
    [14]
    He Q,Zhang J,Chen F,et al.An anti-ROS/hepatic fibrosis drug delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles[J].Biomaterials,2010,31(30):7785-7796.
    [15]
    Nishimori H,Kondoh M,Isoda K,et al.Silica nanoparticles as hepatotoxicants[J].Eur J Pharm Biopharm,2009,72(3):496-501.
    [16]
    Chen Q, Xue Y, Sun J. Kupffer cell-mediated hepatic injury induced by silica nanoparticles in vitro and in vivo[J].Int J Nanomed,2013,8:1129-1140.
    [17]
    Liu T,Li L,Fu C,et al.Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles[J].Biomaterials,2012,33(7):2399-2407.
    [18]
    Isoda K,Hasezaki T,Kondoh M,et al.Effect of surface charge on nano-sized silica particles-induced liver injury[J].Pharmazie,2011,66(4):278-281.
    [19]
    Kabir N,Ali H,Ateeq M,et al.Silymarin coated gold nanoparticles ameliorates CCl4-induced hepatic injury and cirrhosis through down regulation of hepatic stellate cells and attenuation of Kupffer cells[J].RSC Adv,2014,4:9012-9020.
    [20]
    Bartneck M,Ritz T,Keul HA,et al.Peptide-functionalized gold nanorods increase liver injury in hepatitis[J].ACS Nano,2012,6(10):8767-8777.
    [21]
    Choi K,Riviere JE,Monteiro-Riviere NA.Protein corona modulation of hepatocyte uptake and molecular mechanisms of gold nanoparticle toxicity[J].Nanotoxicology,2017,11(1):64-75.
    [22]
    Iimuro Y,Nishio T,Morimoto T,et al.Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J].Gastroenterology,2003,124(2):445-458.
    [23]
    Arias M,Sauer-Lehnen S,Treptau J,et al.Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats[J].BMC Gastroenterol,2003,3:29.
    [24]
    Chen P,Li J,Huo Y,et al.Adenovirus-mediated expression of orphan nuclear receptor NR4A2 targeting hepatic stellate cell attenuates liver fibrosis in rats[J].Sci Rep,2016,6:33593.
    [25]
    Kinoshita K,Iimuro Y,Otogawa K,et al.Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats[J].Gut,2007,56(5):706-714.
    [26]
    Kim JK, Lee JI, Paik YH, et al. A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats[J].J Gene Med,2016,18(1/2/3):16-26.
    [27]
    Rezvani M,Español-Suñer R,Malato Y,et al.In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis[J].Cell Stem Cell,2016,18(6):809-816.
    [28]
    Song G,Pacher M,Balakrishnan A,et al.Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis[J].Cell Stem Cell,2016,18(6):797-808.
    [29]
    Lee YS,Jeong WI.Retinoic acids and hepatic stellate cells in liver disease[J].J Gastroenterol Hepatol,2012, 27:75-79.
    [30]
    Kawaguchi R,Yu J,Honda J,et al.A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A[J].Science,2007,315(5813):820-825.
    [31]
    Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol,2008,26(4):431-442.
    [32]
    Zhang Z, Wang C, Zha Y, et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy[J].ACS Nano,2015,9(3):2405-2419.
    [33]
    Duong HT,Dong Z,Su L,et al.The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension[J].Small,2015,11(19):2291-2304.
    [34]
    Marcelino J,Mcdevitt CA.Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen[J].Biochim Biophys Acta,1995,1249(2):180-188.
    [35]
    Beljaars L,Molema G,Schuppan D,et al.Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor[J].J Biol Chem,2000,275(17):12743-12751.
    [36]
    Yang J,Hou Y,Ji G,et al.Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats[J].Eur J Pharm Sci,2014,52:180-190.
    [37]
    Li F,Sun JY,Wang JY,et al.Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis[J].J Control Release,2008,131:77-82.
    [38]
    Beljaars L, Olinga P, Molema G, et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin(M6P(28)-HSA)[J].Liver,2001,21(5):320-328.
    [39]
    Beljaars L,Molema G,Weert B,et al.Albumin modified with mannose 6-phosphate:a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells[J].Hepatology,1999,29(5):1486-1493.
    [40]
    Luk JM,Zhang QS,Lee NP,et al.Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model[J].Liver Int,2010,27(4):548-557.
    [41]
    Ye Z,Cheng K,Guntaka RV,et al.Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells.[J].Biochemistry,2005,44(11):4466-4476.
    [42]
    Borkham-kamphorst E,Kovalenko E,Roeyen CR,et al.Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury[J].Lab Invest,2008,88(10):1090-1100.
    [43]
    Bansal R,Prakash J,de Ruijter M,et al.Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis[J].Mol Pharm,2011,8(5):1899-1909.
    [44]
    Bansal R,Prakash J,De Ruiter M,et al.Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J].J Control Release,2014,179(1):18-24.
    [45]
    Craparo EF,Triolo D,Pitarresi G,et al.Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes[J].Biomacromolecules,2013,14(6):1838-1849.
    [46]
    Morille M,Passirani C,Letrou-Bonneval E,et al.Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting[J].Int J Pharm,2009,379(2):293-300.
    [47]
    Mandal AK,Das S,Basu MK,et al.Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis[J].J Parmacol Exp Ther,2007,320(3):994-1001.
    [48]
    Mao SJ,Hou SX,He R,et al.Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes[J].World J Gastroentero,2005,11(20):3075-3079.
    [49]
    Liang B,Guo XL,Jin J,et al.Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury[J].World J Gastroentero,2015,21(17):5271-5280.
    [50]
    Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis[J].J Hepatol,2014,60(5):1090-1096.
    [51]
    Bagalkot V,Deiuliis JA,Rajagopalan S,et al.“Eat me” imaging and therapy[J].Adv Drug Deliver Rev,2016,99(Pt A):2-11.
    [52]
    Ogawa M,Uchino R,Kawai A,et al.PEG modification on(111)In-labeled phosphatidyl serine liposomes for imaging of atherosclerotic plaques[J].Nucl Med Biol,2015,42(3):299-304.
    [53]
    Wang J,Pan W,Wang Y,et al.Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis[J].Drug Deliv,2018,25(1):1-11.
    [54]
    Zhang YN,Poon W,Tavares AJ,et al.Nanoparticle-liver interactions:cellular uptake and hepatobiliary elimination[J].J Control Release,2016,240:332-348.
    [55]
    Bonepally CR,Gandey SJ,Bommineni K,et al.Preparation,characterisation and in vivo evaluation of silybin nanoparticles for the treatment of liver fibrosis[J].Trop J Pharm Res,2013,12(1):1-6.
    [56]
    Wan AN, Xu DS, Cai YF, et al. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J].J China Pharm Univ(中国药科大学学报),2017,48(4):476-482.
    [57]
    Bataller R,Brenner DA.Liver fibrosis[J].J Clin Invest,2005,115(2):209-218.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(9)

    1. 蔡鸿飞，张琴，关伟键，杨阳，袁诚，许文东. 不同干燥方式对灵芝孢子粉中灵芝孢子油过氧化值的影响. 广东化工. 2024(01): 28-30 .
    2. 林志彬. 灵芝孢子油的药效物质基础研究进展. 菌物研究. 2024(01): 79-87 .
    3. Jianying Liu，Binzhi Zhang，Leqi Wang，Shasha Li，Qinqiang Long，Xue Xiao. Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: A review. Chinese Herbal Medicines. 2024(03): 375-391 .
    4. 武美华，张胜男，敬隆鑫，律凤霞. 灵芝的活性成分及其药理作用的研究进展. 中国林副特产. 2023(02): 76-79 .
    5. 夏凤娜，关小莺，陈少丹，陈秋颜，张一帆，杨小兵. 灵芝孢子粉脂质成分HPLC-ELSD指纹图谱构建及含量测定. 食用菌学报. 2023(06): 52-59 .
    6. 井子良，吴纯宇，张慧敏，孙建博. 灵芝孢子油番茄红素复合物的抗肿瘤作用. 现代食品科技. 2022(09): 46-51 .
    7. 李志强，何玉霞. 灵芝多糖对人肺癌A549细胞增殖凋亡的作用. 现代食品科技. 2021(05): 38-42 .
    8. 张琴，李康强，杨阳，张圳，蔡鸿飞，许文东. 不同提取方式的灵芝孢子油品质研究. 广东化工. 2021(11): 48-49 .
    9. 包县峰，徐勇，刘维明，王星丽，孙培龙，张安强. 灵芝孢子粉生物活性成分及药理作用. 食品工业科技. 2020(06): 325-331 .

    Other cited types(6)

Catalog

    Get Citation
    PDF
    XML
    Article views (1054) PDF downloads (1926) Cited by(15)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：286500

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return